A number of investment brokers have recently updated their price targets on shares of Chemours (NYSE:CC). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

04/18/2016 – Chemours had its “neutral” rating reiterated by analysts at Citigroup. They now have a USD 8 price target on the stock.

03/14/2016 – Chemours was upgraded to “buy” by analysts at Goldman Sachs. They now have a USD 10 price target on the stock.

02/16/2016 – Chemours was downgraded to “hold” by analysts at Jefferies. They now have a USD 4.5 price target on the stock.

12/18/2015 – Chemours had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 14 price target on the stock.

09/18/2015 – Argus began new coverage on Chemours giving the company a “hold” rating.

08/18/2015 – Chemours was downgraded to “sell” by analysts at UBS. They now have a USD 9 price target on the stock.

08/07/2015 – Chemours was upgraded to “neutral” by analysts at JP Morgan. They now have a USD 11 price target on the stock.

07/28/2015 – Susquehanna began new coverage on Chemours giving the company a “neutral” rating. They now have a USD 13 price target on the stock.

The share price of Chemours (NYSE:CC) was up +3.95% during the last day of trading, with a day high of 10.29. 2154104 shares were traded during the last session.

The stock’s 50 day moving average is 8.18 and its 200 day moving average is 6.10. The stock’s market capitalization is 1.86B. Chemours has a 52-week low of 3.06 and a 52-week high of 22.25.

View other investors thoughts on Chemours with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.